HOME >> BIOLOGY >> NEWS
New Class Of Protease Inhibitors May Be Effective In Treating One Of Latin,,America's Most Devastating Diseases

SAN FRANCISCO, Calif.--Researchers at the San Francisco Veterans Affairs Medical Center and UC San Francisco have demonstrated that a type of drug known as a cysteine protease inhibitor may be highly effective against American trypanosomiasis or Chagas1 disease, which is caused by an infection with the parasite Trypansoma cruzi (T. cruzi).

Chagas is the leading cause of heart disease in Latin America and approximately 50,000 people die every year as a result of it. Once confined to Latin America, cases of Chagas1 disease have been reported in the United States. The study provides proof that this new class of protease inhibitors can be safely used in animals to treat a parasitic infection, the researchers said.

The study, published in the August 17 issue of the Journal of Experimental Medicine, reports on the treatment of 21 mice infected with lethal doses of T. cruzi. All of the treated mice were rescued from the infection. A control group of untreated mice all died within four to ten days. Some of the treated mice were followed for as long as a year with no evidence of disease or parasites.

Importantly, the cysteine protease inhibitors produced no side-effects in the animals, and there was no indication of drug resistance. According to senior author James H. McKerrow, MD, PhD, director of the National Institutes of Health-sponsored Tropical Disease Research Unit at the San Francisco VA Medical Center, and UCSF professor of pathology and pharmaceutical chemistry, the study demonstrates in mice that cysteine protease inhibitors stop T. cruzi from replicating by 3turning off2 a specific enzyme critical to the parasite1s survival -- much like aspartate protease inhibitors work against Human Immunodeficiency Virus (HIV).

Because cysteine and aspartate protease inhibitors function in similar ways, the researchers are optimistic about the drug1s safety and efficacy in humans.

While its potential as a Chagas treatment is very encouraging, perhaps
'"/>

Contact: James Larkin
jlarkin@itsa.ucsf.edu
(415) 750-6633
University of California - San Francisco
18-Aug-1998


Page: 1 2 3

Related biology news :

1. New Class Of Synthetic Capsules That Mimic Biological Cells Has Wide Array Of Potential Uses
2. New Class Of Molecular Cues Guides Nervous System Wiring
3. University Of Kentucky Professor Teaches First Reproductive Laboratory Science Class In The United States
4. Severity Of Classic Heat Stroke Recognized
5. Rapid Progress Reported On New Class Of Anti-Cancer Drugs
6. Bacterial Protein Structure Hints At Mechanism Of A Class Of Premature Aging Diseases
7. Protease-inhibitor cocktail protects, increases anti-microbial action of promising new peptide
8. Use Of Protease Inhibitors For HIV Associated With Dramatic Rise In Oral Warts
9. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
10. HIV-Positive Injection Drug Users Often Dont Receive Protease Inhibitors And May Not Be Aware Of The Drug
11. Researchers Document Transmission Of Protease-Resistant HIV

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2019)... ... April 23, 2019 , ... ... testing instruments for the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries’ is ... in Egg Harbor Township, New Jersey. The new facility was custom designed to ...
(Date:4/25/2019)... ... April 24, 2019 , ... NDA Partners Chairman Carl Peck, ... years of experience in the development of drug and genomic diagnostic products for therapeutic ... to joining NDA Partners, Dr. Maddala served as Vice President of Biometrics at GRAIL, ...
(Date:4/25/2019)... (PRWEB) , ... April 25, 2019 , ... ... as well as screening tools, has strengthened its commitment to meeting today’s highest ... used in any application where inhibition of its targeted proteases is needed. Current ...
Breaking Biology News(10 mins):
(Date:4/4/2019)... ... April 03, 2019 , ... LeadingBiotech, an exclusive event series ... announces its Boston CEO conference to be held May 28-29, 2019 at Boston’s ... with high-level panels and discussions from past, present and future change-makers. ...
(Date:3/27/2019)... , ... March 26, 2019 , ... A leader in ... cell services to veterinarians across the United States and Canada since 2004. The ... and soft tissue injuries in the dog, cat, and horse. Recently, VetStem ...
(Date:3/27/2019)... ... ... Lachman is sponsoring the event on April 1-4, where they will be located ... on site will be available to discuss strategies and tactics to support Facilities of ... Executives from Lachman participating at this year’s conference include Fran Zipp, President & CEO, ...
(Date:3/23/2019)... ... March 22, 2019 , ... Tosoh Bioscience ... Scattering (MALS) detector , offering a revolutionary approach for the measurement of molecular ... biopolymers. A novel optical design, a unique cell-block assembly, and a new calculation ...
Breaking Biology Technology:
Cached News: